Digests

April 2026

Last Month in Ovarian Cancer Research

April was a particularly eventful month for the ovarian cancer community, with significant phase 3 trial results published for the treatment of platinum-resistant disease, new real-world data on PARP inhibitors, and a wave of research on surgical decision-making, survivorship, and the experiences of family caregivers.

April 2026

Last Month in Cervical Cancer Research

April brought a wide range of relevant research, with the strongest open-access evidence concentrated in three areas: immunotherapy combinations for people with recurrent or metastatic disease, a landmark modeling study on how the United States should adapt its screening guidelines, and a sustained focus on the equity gaps that remain the defining obstacle to to eliminating a preventable cancer.

April 2026

Last Month in Uterine Cancer Research

April brought a diverse set of research on uterine and endometrial cancer, with the strongest threads running through surgical outcomes, the growing complexity of molecular tumor classification, and early findings on how the immune system - including the bacteria that live in uterine tissue - may shape how cancer behaves.

April 2026

Last Month in Vaginal Cancer Research

April was a modest month for vaginal cancer literature, yielding four open-access papers directly relevant to this community: a meta-analysis on treatment outcomes for high-grade precancerous lesions, a surgical case report on managing post-radiation recurrence, a systematic review on a rare condition linked to vaginal and cervical cancer, and a review of sexual health in gyne cancer survivors.